Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Carbognin, Luisa; Sperduti, Isabella; Nortilli, Rolando; Brunelli, Matteo; Vicentini, Cecilia; Pellini, Francesca; Pollini, Giovanni Paolo; Giannarelli, Diana; Tortora, Giampaolo; Bria, Emilio
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 3(2015)
• Page Start: 262
• Page End: 270
• Publication Date: 2015-03
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.02.003
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title id="st005">Highlights</title> <sec> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0005">Data were gathered from 15 trials evaluating neoadjuvant paclitaxel and docetaxel for HER2-positive breast cancer.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0010">Neoadjuvant paclitaxel determines a slight significant benefit in terms of pCR in comparison with docetaxel.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0015">Docetaxel significantly increases severe and febrile neutropenia, while paclitaxel slightly worsens neurotoxicity.</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0020">Overall, the benefit/risk analysis balancing activity (pCR) with toxicity (severe neutropenia) supports to use paclitaxel.</p> </list-item> <list-item id="o0025"> <label></label> <p id="p0025">The non-prospective nature of the analysis and its heterogeneity may limit the interpretation of the results.</p> </list-item> </list> </p> </sec> </abstract>